Digital breast tomosynthesis (DBT) changed what a mammography room can detect, and practices that upgraded to 3D capability generally did not look back. The system acquires X-ray images through the breast at multiple angles in a single sweep, then reconstructs thin cross-sectional slices that radiologists scroll through like a CT, separating overlapping tissue layers that 2D mammography stacks together. The result is fewer false-positive recalls on dense tissue and better lesion visibility in tissue types where conventional 2D mammography struggles most. For programs where that clinical gap matters to patients and referring physicians alike, the tomosynthesis investment is not difficult to justify.
New 3D tomosynthesis systems from Hologic, GE, Siemens, Fujifilm, and Canon range from approximately $180,000 to $350,000 depending on configuration and whether a biopsy module is included. Refurbished tomosynthesis systems are available in a narrower price band. We finance new and used 3D tomosynthesis mammography systems starting at $50,000, with application-only approvals available to approximately $400,000 and vendor closing after imaging-package review.
How Tomosynthesis Systems Work and What They Cost
During a tomosynthesis acquisition, the X-ray tube arm sweeps through an arc (typically 15 to 25 degrees depending on manufacturer) while the detector remains stationary. This motion generates a series of low-dose projection images (15 to 25 projections depending on the sweep angle) that the reconstruction software processes into 1 mm slices through the breast. Radiologists read those slices along with a synthetic 2D image generated from the tomosynthesis dataset, eliminating the need for a separate full-dose 2D acquisition in most protocols and keeping total dose at or below the level of 2D mammography alone.
The Hologic Selenia Dimensions was the first FDA-approved tomosynthesis system and remains the most widely installed. The Hologic 3Dimensions represents the current-generation Hologic platform with improved reconstruction speed and image quality. GE's Senographe Pristina with tomosynthesis option, Siemens Mammomat Revelation, and Fujifilm ASPIRE Cristalle are competing platforms with different acquisition geometries and processing approaches. Each has specific workflow characteristics that appeal to different radiologist preferences and practice environments.
System cost varies by manufacturer, configuration, and whether a stereotactic biopsy attachment is included. A base tomosynthesis unit typically runs $180,000 to $250,000 new. Adding a stereotactic biopsy module adds another $50,000 to $100,000. Refurbished first-generation systems are available significantly below those price points but require careful evaluation of detector condition and software currency.
Programs Financing 3D Tomosynthesis Systems
The primary buyer for a tomosynthesis system upgrade is a screening mammography program that is losing or at risk of losing referrals to competitors who have already upgraded. The recall rate and detection sensitivity differences between 2D and 3D mammography are well enough established in the literature that many referring OB/GYN practices, primary care physicians, and oncologists have begun directing patients specifically to tomosynthesis-equipped centers. A program still running 2D-only screening faces a competitive disadvantage that grows each year as 3D becomes the expected standard.
De novo women's health centers and outpatient imaging centers starting fresh almost universally equip with tomosynthesis from the outset. The capital premium over a 2D-only unit is modest relative to the total startup investment, and the competitive differentiation is immediate. For those programs, financing the 3D unit rather than the less-capable 2D alternative is the straightforward choice.
Oncology and radiation centers that screen high-risk patients are also significant tomosynthesis buyers. High-risk screening programs rely on sensitivity over specificity, and tomosynthesis's better lesion visibility in dense breast tissue directly serves that patient population. For oncology programs, the clinical case for tomosynthesis is stronger than for general population screening.
Financing a 3D Tomosynthesis System
Tomosynthesis system transactions most commonly fall running about $180k to $350k, which often fits within application-only approval limits. A completed application with the vendor quote or purchase agreement is the starting point. For deals under $400,000, we target a decision within 24 to 48 hours on complete applications. Funding typically closes one to two weeks from approval.
Practices upgrading from an existing 2D mammography system can finance the tomosynthesis upgrade as a standalone transaction when the project clears the $50,000 floor and the existing system is a compatible platform. The upgrade invoice replaces the full-system invoice in the documentation package. Trade-in of the existing system can reduce the net financed amount when the vendor accepts the old unit toward the upgrade purchase.
For programs adding both the tomosynthesis system and a biopsy attachment simultaneously, combining both components in a single financing transaction is cleaner than handling them separately. We structure combined equipment loans and leases that cover both the base system and the add-on components under one approval. X-ray equipment leasing is worth evaluating for programs that anticipate upgrading to the next generation of tomosynthesis technology within five to seven years, as the fair market value lease preserves that upgrade optionality at term end.
Refinancing or Sale-Leaseback on an Existing Tomosynthesis System
Programs that purchased a tomosynthesis system outright two to five years ago and have built up equity in the asset may find a Sale-Leaseback Financing useful for extracting working capital without taking on unsecured debt. The asset is sold to the lender and leased back, generating immediate cash while the practice continues using the system without interruption. For women's health centers managing cash flow around insurance reimbursement cycles, converting equipment equity to operating capital can fund marketing, staffing, or a second room build without straining the operating account.
Refinancing an existing tomosynthesis loan to a lower rate or longer term is also available when the practice's credit profile has improved since the original purchase. An improved rate directly reduces monthly cash outlay, freeing margin for other investments in the imaging center's growth. Practices that want to pull working capital from a tomosynthesis system while retaining use of it can also review cash-out equipment refinance options alongside the pure sale-leaseback structure to see which produces the better net outcome for their specific equity position. Outpatient imaging centers running active tomosynthesis programs are well-positioned for either structure because the equipment has strong residual value relative to its original cost.
Related Financing Paths
Questions about 3D Tomosynthesis Mammography Systems Financing
Clear answers on equipment eligibility, documentation, timing, and the financing path before you send the full file.
Are there reimbursement differences between 2D and 3D tomosynthesis that affect the financing math?
Yes. CMS reimburses a separate add-on CPT code for the tomosynthesis component when performed alongside a 2D or synthesized 2D view. The reimbursement varies by payer and contract, but most commercial payers also cover tomosynthesis screening. Programs evaluating the upgrade should model the reimbursement difference per study against the monthly payment increment to establish the break-even timeline.
Can a single-location imaging center with two years of operating history qualify for tomosynthesis financing?
Yes, two years of operating history with consistent revenue is a solid foundation for an equipment financing application. Three months of bank statements demonstrating stable deposits, along with the application, is typically sufficient for transactions landing between $200k and $350k.
We have dense breast reporting laws in our state that require notifying patients. Does that drive more practices toward tomosynthesis?
Dense breast notification laws have contributed to patient and provider awareness of mammography's limitations in dense tissue, which has supported tomosynthesis adoption in states with those requirements. That market dynamic does not change the financing terms, but it does affect the competitive positioning of programs that have not yet upgraded.
Can I finance a tomosynthesis system that a vendor is installing in our existing X-ray room versus a purpose-built mammography suite?
Mammography systems require a dedicated room with appropriate shielding; they are not typically installed in general X-ray rooms. Room shielding, which is specific to mammography X-ray energy and geometry, can be included in the financing when it is part of the same project. A mammography physics consultation should establish the room requirements before finalizing the installation plan.
What happens to our tomosynthesis system lease at end of term?
Under a fair market value lease, you have the option to purchase the equipment at its then-current fair market value, continue leasing, or return the equipment. Under a dollar-buyout lease, you purchase the equipment for one dollar at end of term and own it outright. The right choice depends on whether you expect to upgrade to next-generation equipment at term end or prefer long-term ownership of the current system.
Bring this system into your room.
Send the 3D Tomosynthesis Mammography Systems Financing quote, seller details, requested amount, and installation target. The imaging finance desk will map the next practical step.